• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Nightingale joins wellbeing services county research project

HEALTHAnalyst Comment2026-05-29 08:46
Antti SiltanenAnalyst
Discuss

Summary

  • Nightingale Health is participating in a research project with Etelä-Savo wellbeing services county, combining its blood analysis technology with digital lifestyle coaching.
  • The project, called Hyvinvointilahja, offers free health assessments to certain age groups and aims to evaluate the effectiveness of this model in public healthcare.
  • The initiative is limited in scope and does not immediately impact financial forecasts, but it serves as a strategic reference for potential future adoption in the public sector.
  • For Nightingale to achieve profitability, it needs to convert these pilot projects into continuous, high-volume use in public healthcare, which remains a slow-moving sector.

This content is generated by AI. You can give feedback on it in the Inderes forum.

Translation: Original published in Finnish on 5/29/2026 at 7:00 am EEST.

Nightingale Health announced on Thursday that it is participating in a research and development project initiated by the Etelä-Savo wellbeing services county, Eloisa, in which the company's blood analysis technology is combined with digital lifestyle coaching. The start of the project is the first practical step in the collaboration the parties already announced in June 2025. Although this is an encouraging opening in the public primary healthcare sector, the project is limited in scope as a research initiative, and therefore the announcement does not cause immediate changes to our forecasts.

Piloting towards public healthcare clients

In the Hyvinvointilahja project (“Wellbeing Gift”), 45-, 50-, and 55-year-olds in the Eloisa region are offered a free health assessment, and individuals with an elevated risk are referred to lifestyle counseling. The project will be implemented between March 2026 and April 2027, and it is funded by Sitra and Eloisa. Nightingale is aiming for breakthroughs in the public healthcare sector, which is a huge potential target market for the company, but at the same time, a very slow-moving and conservative sector. The project's goal is specifically to evaluate the effectiveness of the operating model before any potential wider implementation.

Financial potential will only be measured upon potential wider adoption

While the project is a strategically important reference from the public sector, its immediate financial size will likely remain quite moderate on the company's scale. In our view, turning Nightingale's business model profitable requires revenue to multiply and a continuous stream of significant commercial sample volumes. We are following the results of the project with interest, but what is decisive for the valuation and investment story is whether Nightingale can turn these fixed-term pilots into continuous, high-volume routine use in public healthcare.

 

Nightingale Health operates in the medical technology sector. The company specializes in the development of medical technology products. The product portfolio is broad and includes platforms and services within blood analysis that are used for disease prevention purposes. In addition to the main business, service and related ancillary services are also offered. The business is operated globally with the largest presence in Europe.

Read more on company page

Key Estimate Figures05/03

202526e27e
Revenue4.77.98.3
growth-%7.7 %68.5 %4.3 %
EBIT (adj.)-19.4-16.5-14.4
EBIT-% (adj.)-413.7 %-208.1 %-174.1 %
EPS (adj.)-0.30-0.26-0.22
Dividend0.000.000.00
Dividend %
P/E (adj.)neg.neg.neg.
EV/EBITDAneg.neg.neg.

Forum discussions

The AI reports the following. Note that the answers may contain errors. The Swedish remote health service company Supernormal and the Finnish...
4 hours ago
by Pertti
5
There are no details on how to use the Nightingale test on the site, even though it is clearly mentioned under the Provtagningsnätverk (sampling...
4 hours ago
by The Ugly Buckling
0
Nightingale scores used in sampling, as mentioned? At least it wasn’t mentioned on the analysis side of the website.
7/26/2026, 10:20 AM
0
It seems that the Swedish telehealth company Supernormal uses Nightingale’s blood test as part of providing its services. According to their...
7/26/2026, 7:56 AM
by The Ugly Buckling
12
Nightingale now has two commercial directors in Japan. In addition, Kyoko Harimoto will join from August 2025. There has been no progress in...
7/26/2026, 7:49 AM
by Monsieur
6
Yu Kato started as the Commercial Director for Nightingale’s research sales in Japan in June. Kato moves to the position from Olink Proteomics...
7/26/2026, 7:21 AM
by The Ugly Buckling
7
The website kukaomistaa.fi, through which you can view information about the owners of companies listed on the Helsinki Stock Exchange. You ...
7/18/2026, 5:49 PM
by The Ugly Buckling
5